Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedJan 08, 2026
DataAggregated Company Financials
Companies58
  • 7D-2.8%
  • 3M-9.5%
  • 1Y11.7%
  • YTD-2.4%

Over the last 7 days, the Pharma industry has dropped 1.4%, driven by Caliway Biopharmaceuticals declining 8.7%. Meanwhile, ScinoPharm Taiwan actually outperformed within the industry, gaining 23% in the last week. In the past year, the industry has gained 13%. Looking forward, earnings are forecast to grow by 87% annually.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 08 Jan 2026NT$720.5bNT$118.0bNT$12.3b16.6x58.6x6.1x
Sat, 06 Dec 2025NT$781.2bNT$118.0bNT$12.3b16.9x63.5x6.6x
Mon, 03 Nov 2025NT$752.1bNT$118.3bNT$9.6b16x78.1x6.4x
Wed, 01 Oct 2025NT$828.2bNT$118.3bNT$9.6b16.5x86.3x7x
Fri, 29 Aug 2025NT$799.8bNT$118.4bNT$10.3b16.3x77.7x6.8x
Sun, 27 Jul 2025NT$692.6bNT$116.0bNT$14.3b18.4x48.5x6x
Tue, 24 Jun 2025NT$656.9bNT$115.9bNT$14.3b18.4x46.1x5.7x
Thu, 22 May 2025NT$605.8bNT$115.9bNT$14.3b19.4x42.5x5.2x
Sat, 19 Apr 2025NT$535.9bNT$112.8bNT$10.8b18x49.6x4.8x
Mon, 17 Mar 2025NT$644.9bNT$113.3bNT$12.2b20.3x52.7x5.7x
Wed, 12 Feb 2025NT$665.8bNT$109.3bNT$11.4b22.6x58.2x6.1x
Fri, 10 Jan 2025NT$609.1bNT$109.3bNT$11.4b21.7x53.3x5.6x
Sun, 08 Dec 2024NT$610.3bNT$109.3bNT$11.4b22x53.3x5.6x
Tue, 05 Nov 2024NT$631.5bNT$104.7bNT$8.9b26.4x70.6x6x
Thu, 03 Oct 2024NT$646.3bNT$104.7bNT$8.9b25.6x72.3x6.2x
Sat, 31 Aug 2024NT$664.5bNT$104.7bNT$8.9b26.6x74.3x6.3x
Mon, 29 Jul 2024NT$678.8bNT$100.5bNT$6.8b31.7x99.4x6.8x
Wed, 26 Jun 2024NT$659.9bNT$100.4bNT$7.2b30.9x92.2x6.6x
Fri, 24 May 2024NT$622.8bNT$100.4bNT$7.1b30.8x87.1x6.2x
Sun, 21 Apr 2024NT$605.4bNT$101.8bNT$9.4b24.6x64.7x5.9x
Tue, 19 Mar 2024NT$620.0bNT$100.9bNT$9.5b25.3x65.4x6.1x
Thu, 15 Feb 2024NT$597.8bNT$101.6bNT$8.2b23.4x73.3x5.9x
Sat, 13 Jan 2024NT$575.6bNT$101.9bNT$7.8b24.2x73.9x5.7x
Mon, 11 Dec 2023NT$577.9bNT$101.6bNT$7.6b23.8x75.8x5.7x
Wed, 08 Nov 2023NT$569.2bNT$101.8bNT$9.7b22.5x58.7x5.6x
Fri, 06 Oct 2023NT$550.4bNT$101.7bNT$9.6b21.7x57.2x5.4x
Sun, 03 Sep 2023NT$562.3bNT$101.7bNT$9.6b22.5x58.4x5.5x
Tue, 01 Aug 2023NT$578.5bNT$98.7bNT$10.1b16.7x57.5x5.9x
Thu, 29 Jun 2023NT$599.7bNT$98.7bNT$10.1b17.1x59.6x6.1x
Sat, 27 May 2023NT$575.1bNT$97.9bNT$10.7b18.3x53.9x5.9x
Mon, 24 Apr 2023NT$560.5bNT$91.7bNT$8.7b21.7x64.3x6.1x
Wed, 22 Mar 2023NT$534.8bNT$90.2bNT$7.8b19.8x68.6x5.9x
Fri, 17 Feb 2023NT$547.6bNT$84.6bNT$7.9b24x69.4x6.5x
Sun, 15 Jan 2023NT$471.3bNT$84.6bNT$7.9b19.7x59.8x5.6x
Price to Earnings Ratio

59.8x


Total Market Cap: NT$471.3bTotal Earnings: NT$7.9bTotal Revenue: NT$84.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 65.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Taiwanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 59.1x which is lower than its 3-year average PE of 65.9x.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 16% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare industry?

TW Market4.80%
Healthcare-1.42%
Pharma-2.75%
Pharma-2.75%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
1789 ScinoPharm TaiwanNT$20.6523.3%
+NT$3.1b		-7.2%PE84.6x
4743 Oneness BiotechNT$60.909.5%
+NT$2.5b		-28.4%PS248.3x
6472 Bora PharmaceuticalsNT$495.001.4%
+NT$868.2m		-22.3%PE14.5x
7878 PharmasagaNT$250.006.6%
+NT$829.8m		n/an/a
4130 Genovate BiotechnologyNT$32.0015.5%
+NT$489.1m		56.5%PE333.2x

Latest News

4743
NT$60.90
Oneness Biotech
7D
9.5%
1Y
-28.4%
1795
NT$281.00
Lotus Pharmaceutical
7D
-0.7%
1Y
2.4%

1795: Southeast Asia Presbyopia NDA Will Support Future Share Price Upside

Analysts kept their fair value estimate for Lotus Pharmaceutical steady at $395.20, with only minor tweaks to revenue growth, profit margin, discount rate and future P/E assumptions behind the updated target. What's in the News Lotus Pharmaceutical and LENZ Therapeutics reported that Lotus has submitted a New Drug Application to South Korea's Ministry of Food and Drug Safety for VIZZTM, a presbyopia treatment for adults, under their exclusive license and commercialization agreement signed in May 2025 for South Korea and certain Southeast Asian markets (Key Developments).
1789
NT$20.65
ScinoPharm Taiwan
7D
23.3%
1Y
-7.2%
6461
NT$19.65
Intech Biopharm
7D
10.4%
1Y
-24.0%
6785
NT$278.00
Alar Pharmaceuticals
7D
-8.6%
1Y
100.7%
6472
NT$495.00
Bora Pharmaceuticals
7D
1.4%
1Y
-22.3%

6472: Alliance With Corealis Will Support Stronger Long Term Performance

Analysts have modestly reiterated their outlook on Bora Pharmaceuticals, keeping the fair value estimate steady at $788.87 per share, as they see no material changes to projected revenue growth, margins, or valuation multiples. What's in the News Bora Pharmaceuticals and Corealis Pharma formed a strategic alliance to deliver integrated end to end oral solid dose development and manufacturing services, giving clients a single pathway from early formulation through commercial production (company announcement) The partnership combines Bora's global commercial infrastructure with Corealis' formulation and clinical scale manufacturing expertise, aiming to accelerate timelines and reduce complexity for biotech and pharma innovators (company announcement) Bora and Corealis will align project management and quality systems across the drug development lifecycle to lower outsourcing risk and improve reliability from discovery through commercial launch (company announcement) Valuation Changes Fair Value Estimate is unchanged at NT$788.87 per share, indicating no revision to Bora Pharmaceuticals' intrinsic value assessment.
6919
NT$141.50
Caliway Biopharmaceuticals
7D
-8.7%
1Y
132.3%
4167
NT$17.45
Savior Lifetec
7D
-5.2%
1Y
-17.1%
4166
NT$27.75
Orient Pharma
7D
6.1%
1Y
-23.0%
4114
NT$32.95
Synmosa Biopharma
7D
1.7%
1Y
5.2%
4130
NT$32.00
Genovate Biotechnology
7D
15.5%
1Y
56.5%
4123
NT$39.40
Center Laboratories
7D
-5.3%
1Y
-3.2%
6535
NT$183.00
Lumosa Therapeutics
7D
-5.9%
1Y
-24.4%
1271
NT$55.10
SunWay Biotech
7D
-7.2%
1Y
-26.9%
6586
NT$26.05
CHO Pharma
7D
-7.3%
1Y
-49.1%